Findings

What do systematic reviews say?

6 questions · 6 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 33.3%Low 2 · 33.3%Moderate 2 · 33.3%High 0 · 0%

Adverse events · people with bronchiectasis

Inhaled mannitol showed no clear difference in adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Inhaled hyperosmolar agents for bronchiectasis 2014 · Cochrane Headline outcomes only
OR 0.96 [0.61, 1.51]
2 studies · 804 participants
Moderate

Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Low

Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
123 participants
Low

Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 600 participants
Moderate

Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Very low

Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Very low